Congenital heart disease in children
Conditions
Interventions
Group DK2:Dexmedetomidine 3 µg/kg + Eszopiclone 1 mg/kg administered by nasal drip
Group DK1:Dexmedetomidine 3 µg/kg + Eszopiclone 0.5 mg/kg administered by nasal drip
Group D:Dexmedetomidine 3 µg/kg administered by nasal drip
Sponsors
Yan'An hospital of Kunming City
Eligibility
Sex/Gender
All
Age
No minimum to 5 Years
Inclusion criteria
Inclusion criteria: 1.Children with congenital heart disease aged 6 months to 5 years; 2.Children who are unable to complete chest echocardiography after non pharmacological behavior management and require examination under procedural sedation; 3.No drinking or eating for at least 2 hours before sedation. 4.Obtain written informed consent;
Exclusion criteria
Exclusion criteria: 1.Children with advanced upper respiratory tract infection, nosebleeds, nasal tumors, difficult airways, severe cyanotic congenital heart disease, high intracranial pressure, and high intraocular pressure; 2.Children with allergies or severe adverse reactions to research drugs; 3.Children who were drowsy that day and scored less than 5 on the Modified Alert/Sedation Scale (MOASS); 4.Cardiac conduction abnormalities are defined as children with second or third degree heart block;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety indicators;Degree of cooperation;Sedation success rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| The time taken to reach the expected level of sedation;Wake-up time;Adverse reaction;Time to fall asleep;Inspection duration; | — |
Countries
China
Contacts
Public ContactPinyi Lv
Yan'An hospital of Kunming City
Outcome results
None listed